Takeda Says U.S. FDA To Delay Approval Of Replacement Diabetes Drug
This article was originally published in PharmAsia News
Takeda Pharmaceutical said U.S. FDA has delayed review of alogliptin until the Japanese drug maker can supply more data about the diabetes drug. The delay was seen as a blow to Takeda, which faces a 2011 patent expiration on its best-seller Actos (pioglitazone) for treating Type 2 diabetes. Takeda submitted data about the drug candidate at the end of 2007, but FDA said the information did not meet new standards adopted by the agency last year. (Click here for more
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.